JOHNS HOPKINS

TECHNOLOGY VENTURES
FY20 ANNUAL REPORT

Bringing the benefits of

academic discovery
to the world
 FY20 ANNUAL REPORT

A YEAR TO REMEMBER
... And not just for the reasons we anticipated! The coronavirus pandemic
was unexpected and unprecedented. It tested the limits of our flexibility,
resilience — and our technology. The Johns Hopkins Technology Ventures
(JHTV) team continued its work remotely, and had the unique privilege
of supporting researchers and startups in the urgency of the moment.
Our university is a dynamic place, always pulsing with innovation and
creativity, but it was, in many ways, at its best this spring.

Pandemic aside, our new website was launched on the eve of our fifth
anniversary and then quickly put to the test as a key tool for helping
faculty members and students access resources from afar. This year,
we launched our Women in Innovation initiative, supporting female
entrepreneurs across Johns Hopkins. Our student teams participated in
FastForward U‘s student accelerator program, and our student teams
continue to earn recognition across the country. We also embraced
a swell of innovation activity in software, cell and gene therapy, and
precision medicine.

Please read on. We are grateful to serve our students and our faculty,
and we love to share and celebrate their breakthroughs.

Onward,

Christy Wyskiel
Executive Director, JHTV
Senior Adviser to the President
for Innovation and Entrepreneurship
FY20 ANNUAL REPORT

TABLE OF CONTENTS

Year-in-Review 1

Technology Transfer 3

Corporate Partnerships 5

FastForward: Entrepreneurship and Venture Creation 7

Training and Education 11

Acknowledgements 12

What‘s Next? 13
1 FY20 ANNUAL REPORT

YEAR-IN-REVIEW
RANKING LICENSING

7 464
Ranked by the National Academy of
Inventors and the Intellectual Property
Owners Association’s report “Top 100
Worldwide Universities Granted U.S.
REPORTS OF
Utility Patents” INVENTION

10 Named a top 10 university for

startups in IP Watchdog‘s
2008–2018 report $27.3M
LICENSING REVENUE

114
STARTUPS
11 LICENSES
AND OPTIONS

$278M 23
LICENSED
STARTUPS
CREATED 173
LICENSED NEW U.S.
RAISED BY STARTUPS PATENTS

$24M 63 $17.3M
RAISED BY
STUDENT-LED
VENTURES
9
OTHER
CORPORATE-SPONSORED
RESEARCH COLLABORATIONS
MANAGED BY JHTV
VENTURES
CREATED

COVID-19
The pandemic provided the
MARKET SUCCESS
opportunity for Johns Hopkins
startups to pivot their focus in

27
an effort to help those in need
BURNALONG
CLEARMASK
TEAMS RECEIVED EMOCHA MOBILE HEALTH
TRANSLATIONAL Net Health acquired Tissue Analytics, founded
FUNDING TOTALING by Whiting School of Engineering students. This

$3.1M
will expand Net Health‘s leadership position in
the wound care market and will accelerate the
delivery of next generation wound care
technology solutions.
 FY20 ANNUAL REPORT 2

TOP STORIES OF 2020

Our startups and researchers made great strides in their innovations,
attracting industry attention, and funding along the way. The coronavirus
pandemic altered plans for many but also sparked new research and discovery.
The following is a selection of the compelling stories we documented this year.
COVID-19
» Coronavirus Vaccine in Development at Johns Hopkins
» Johns Hopkins Alum’s Skin Care Company Now Producing Hand Sanitizer
» Johns Hopkins Engineers Develop 3D-Printed Ventilator Splitters

STARTUPS
» Thrive Earlier Detection Releases Results of First Study on Multicancer Blood Test
» Galen Robotics Makes Itself at Home in Baltimore with New Offices, Internship Program

STUDENTS
» Student Engineers Design a Solution to Address Common Dialysis Complication
» FastForward U Spark Team Wants to Reinvent the Food App Industry

AWARDS
» Five Johns Hopkins Startups Receive Inaugural Microsoft Acceleration Awards for Artificial
Intelligence and Data Science Technologies

COLLABORATIONS
» Johns Hopkins, Toshiba Collaborate on Precision Cardiovascular Medicine Project
» Basic-Science Researcher Shows Path to Corporate Collaboration

3D Printed Ventilator From the left: Flave co-founders Jal Irani, Galen Robotics‘ president and CEO Bruce
PHOTO: Will Kirk/The Johns Hopkins University Derek Battle, and James Soldinger Lichorowic, second from right, and Dave
PHOTO: Beatrice Shim/FastForward U Saunders, chief technology officer and co-
founder, third from right, with former
Johns Hopkins interns
PHOTO: Galen Robotics
3 FY20 ANNUAL REPORT

TECHNOLOGY TRANSFER
JHTV’s Technology Transfer group is privileged to support the translation of best-in-class science to the
marketplace, so that discoveries can be most impactful in addressing unmet needs. Notwithstanding Johns
Hopkins’ preeminence in life sciences and health care innovation, the technology portfolio is broad, and there
is no ground we are not breaking – literally this year, we licensed a geothermal well technology! As the
university went “remote” this spring in response to COVID-19, our office saw an uptick in faculty interaction —
reports of invention in April and May were up 40%. Licensing activity also grew during that period, with a 25%
increase in license executions.

TECH TRANSFER SNAPSHOT 2020

REPORTS OF INVENTION 464

LICENSING AGREEMENTS 114

ACTIVE PATENTS 3,131

MATERIAL TRANSFER AGREEMENTS 4,973

NONDISCLOSURE AGREEMENTS 438

TRANSLATIONAL FUNDING

$3.1M » BISCIOTTI
AWARDED
» COHEN
27 » THALHEIMER
PROJECTS
A set of philanthropy-enabled translational
funds help investigators advance their early-
stage technologies. Through technology
development and prototyping, these
technologies become stronger candidates for
licensing. From 90 applications, JHTV was able
to support researchers’ goals of building better
batteries, fighting mosquito-borne disease,
perfecting cranial drug delivery, and blocking
cancer metastasis, among others.
FY20 ANNUAL REPORT 4

» COVID-19 INNOVATION
» FEATURED TECHNOLOGIES
JHTV collaborated with Chris Heaney, associate
PREMISE
professor from the Bloomberg School of Public Target Validation of Splicing Repression, a Major
Health, on the commercial development of an Function of TDP-43 in the Motor Neuron
oral diagnostic to measure immune responses PRINCIPAL INVESTIGATOR
(antibody) to SARS-CoV-2 infections. Philip Wong, professor of pathology
PROGRESS
The fundamental cause of amyotrophic lateral
sclerosis (ALS) is unknown. In the last decade,
however, the TDP-43 protein has been shown to
abnormal RNA splicing, which causes loss of motor
neurons in 97% of ALS cases. Wong and his
colleagues have validated a therapeutic strategy
designed to restore the normal splicing of TDP-43 in

» DIGITAL INNOVATION
motor neurons of mice and flies that mimics the loss
of TDP-43 splicing in ALS. Development of this

75
technology may lead to a gene therapy for the
treatment of ALS.

PREMISE
Diffuse-Light-Collecting Microconcentrators for High
of the 464 reported inventions this year were digital Efficiency Solar Cells
innovations. Johns Hopkins is dedicated to making PRINCIPAL INVESTIGATOR
these available through various means, ranging from Susanna Thon, assistant professor of electrical and
traditional licensing to open source licensing. This computer engineering
year, digital innovations were at the core of PROGRESS
51 licenses and the formation of five new Thon and her colleagues at the Whiting School of
licensed startup companies. Engineering have developed and tested
concentrators to maximize light absorption in
third-generation solar cells in a cost-effective way.

» MATERIAL TRANSFER AGREEMENTS

The technology dramatically increases power output
by creating lenses that can be bonded directly to

4,973
solar cells and deliver up to 20 times the current of
existing third-generation technologies.

PREMISE
SulAnchor Cathodes for High Charge/Discharge
Lithium Sulfur Batteries
PRINCIPAL INVESTIGATOR
JHTV’s seven-person contracts team processed V. Sara Thoi, assistant professor, Department of
nearly 4,000 Material Transfer Agreements (MTAs) Chemistry
in the first three quarters of the fiscal year, with PROGRESS
almost 90% processed within five days of receiving These new Lithium-Sulfur (Li-S) batteries could be
used for consumer electronics and large-scale
them and nearly all processed within 30 days. Due
stationary energy storage, as well as in the heavy
to the coronavirus, some companies are providing
electric vehicle industry, in which long range and
access to proprietary materials they previously kept high payload transportation will need high energy,
off limits, and with that allowance comes tighter lightweight batteries. Li-S batteries with SulAnchor
restrictions about use of their materials and the technology also have remarkable energy storage
companies interest in future results. capabilities at various charge and discharge rates,
allowing stable recharging as fast as 15 minutes.
5 FY20 ANNUAL REPORT

CORPORATE PARTNERSHIPS

Redefining best We specialize in facilitating care products and services.

industry collaborations that JHTV also facilitated collaboration
practice in academic translate the novel work of Johns regarding cutting-edge

corporate research Hopkins researchers into therapeutic modalities, including

real-world applications. This year, cell and gene therapies, and
collaboration we began industry collaboration we created a rapid COVID-19
on Johns Hopkins’ precision coordination center to connect
medicine initiative, inHealth, industry with institutional experts.
which leverages university-wide
assets and analytics infrastructure
to develop transformative health

THERAPEUTICS DEVICES, ENGINEERING

Corporate partners are
DIAGNOSTICS, Faculty expertise at the Whiting

critical to our success in

AND SOFTWARE School of Engineering is deep
Industry collaborations in a wide array of research
developing new treatments
in this area are focused areas, and our faculty members
— for Johns Hopkins’ own
on development of novel collaborate frequently at the
patients and populations
diagnostic and data analytics intersection of disciplines
beyond. Our strengths in
platforms and advances in — a great setup for industry
disease biology, discovery
medical image processing and partnerships. This year, we
science, and computer
medical robotics. Our precision established new industry
science/engineering, along
medicine initiative, inHealth, partnerships in the fields of
with our clinical expertise and
has provided a particular point — among others — materials
diverse patient population,
of intersection with industry science (low-cost sensing
complement biopharma’s drug
interest in data-driven, applications; modeling of new
discovery, medicinal chemistry,
hypersegmented approaches materials for novel battery
and manufacturing expertise.
to care management and design), predictive health care
As corporations scaled back
product development. analytics (predictive algorithms
in-house R&D over the past
for intensive care unit clinicians)
decade, Johns Hopkins and
and computational biology
the biopharmaceutical industry
(biophysical modeling to design
have jointly benefited from
antibodies and antigens).
the symbiosis that exists
between us.
 FY20 ANNUAL REPORT 6

COLLABORATION NEWS
Beginning in 2016, AbbVie and The
Johns Hopkins University (JHU)
established an oncology research
collaboration focused on better
mechanistic understanding, validation
of novel targets and biomarkers, and
discovery/development of medicines
for the treatment of cancer. Since
its inception, our scientists have
embarked on multiple projects
together. Many of them are ongoing.

With combined research interests,

innovation, and expertise in oncology
and immunology, Bristol-Myers
Since 2015, Bayer and JHU have
Squibb and JHU have collaborated
been collaborating to jointly develop
over several years to advance medical
new ophthalmic therapies targeting
treatment options for patients. Our
retinal diseases. Two Bayer projects
existing collaborations span both
have achieved major pre-clinical
early-stage target validation and drug
development milestones. The
discovery through clinical development
collaboration has been renewed for a
of promising new therapies for myriad
second term, and six more projects at
cancer and rheumatologic indications.
the Johns Hopkins Wilmer Eye Institute
One of our largest joint programs is
were approved.
focused on identifying mechanisms
of response and resistance to cancer
patients treated with checkpoint
inhibitor-based immunotherapies.

Cannon Medical’s collaboration with

JHU is centered on the company’s
state-of-the-art MRI and ultra-high
resolution CT scanners housed at
the university. This collaboration
spans several departments including
cardiology, radiology, biomedical
engineering (BME), and neurological
surgery. With four ongoing projects,
we anticipate having six additional
active projects by the end of 2020
that will investigate the heart, bones,
lungs, and brain.

The lab of Andy Pekosz, professor

Emphasizing emerging technologies
of molecular microbiology and
to solve critical health problems, DH
immunology at the Bloomberg School
Diagnostics has engaged with research
of Public Health, has established a
and medical faculty for sponsored
human nasal epithelial cell SARS-CoV-2
research, collaborated on a BME
infection model. JHTV/Corporate
student project and sponsored the
Partnership facilitated a partnership
2019 Carey Business School Case
with Takeda to test their proprietary
Competition, taking advantage of the
compounds in this JHU model of
diverse areas of expertise offered
infection to potentially discover novel
through a strong relationship with JHU.
treatments for COVID-19.
7 0010 FY20 ANNUAL REPORT

FASTFORWARD
A coordinated suite of resources designed to
efficiently move technologies from startup
to marketplace. With innovations in an
array of markets from drug development
to manufacturing and digital health,
FastForward startups are bringing myriad
life-changing technologies to market

160
ACTIVE
$278M
VENTURE FUNDING
STARTUPS RAISED BY 23 STARTUPS
FY20
1,280 $3.1M
LOCAL JOBS TRANSLATIONAL FUNDING
AT STARTUPS RAISED BY STARTUPS

INNOVATION HUBS
FastForward provides affordable, turn-key
spaces for our startups at two locations in CLICK BELOW TO SEE HOW OUR HUBS WORK
Baltimore City. This year, our spaces were
home to 41 startup companies, including 13
therapeutics, five diagnostics and 11 health
information technology startups. Critical
research activities continued this spring
during the COVID-19 shutdown, and even
as much activity was remote, all companies
continued to leverage FastForward
membership to access mentorship,
fundraising support, pro bono services
from sponsors, and other support.
 FY20 ANNUAL REPORT 8

STARTUP PORTFOLIO

2014 2015 2016

PROTENUS SONAVEX WINDMIL THERAPEUTICS
Developing insightful Creating novel and automated Translating insights in bone
solutions that remove barriers ultrasound technology that marrow immunology into
to efficient, safe, and effective empowers clinicians with life-saving cell therapies
delivery of patient care actionable data to deliver for cancer patients
superior patient care and
savings to the health
care system

2019 2018 2017

THRIVE DRACEN PHARMACEUTICALS LIFESPROUT
Developing CancerSEEK, a Leveraging immunometabolism to Developing revolutionary
blood-based test designed to be create a potential new treatment products for aesthetic and
affordable and used as part of paradigm with broad application regenerative medicine
routine medical care to detect for many cancer types
multiple types of cancer at earlier
stages, launched with $110 million
in Series A funding

NOTABLE 2020 ACTIVITY

FUNDING COVID-19 EXPANSION

AsclepiX Therapeutics raised $35 million emocha Mobile Health adapted its Columbus, Ohio-based Ready Robotics
in Series A financing, the proceeds of technology to remotely monitor health $23 million to expand its robotic operating
which will fund phase 1/2a clinical trials care workers who have been exposed to system, which allows workers without any
for the treatment of macular conditions. COVID-19. They are working with Johns robotics background or coding experience
AsclepiX uses computational biology to Hopkins Medicine and LifeBridge Health to easily program the robots that
identify potent peptide regulators of affiliated hospitals to identify, track, their plant uses.
vascular homeostasis for the treatment and manage symptoms of workers
of retinal and other important diseases. through video check-ins.
 9 FY20 ANNUAL REPORT

SIGNATURE PROGRAMS
FOR ENTREPRENEURS

Facilitating startup Since 2014, JHTV has advanced innovate or start a business.
innovation ecosystems Our Social Innovation Lab (SIL)
formation and and developed tomorrow’s supports innovative nonprofits,
solutions for today’s biggest mission-driven companies,
growth through a challenges. We are committed to and disruptive technologies to

range of supportive supporting all ventures, including create change and opportunity in
community and student startups. Baltimore and beyond.
programs FastForward U (FFU) is our hub
for student entrepreneurship. It
is a collaborative, extracurricular
environment for any student
looking to experiment,

SIL IMPACT FORUM FFU DEMO DAY BISCIOTTI STUDENT

WINNER WINNER PRIZE WINNER
Bree Jones of Parity was Competing against eight FFU ForagerOne was awarded
awarded the Cohort Prize of Fuel teams, Relavo came out on $30,000 in nondilutive funding.
$25,000 by her peers based on top and won this year’s top prize The team’s mission is to build a
the strength of her progress over of $15,000 during Demo Day. more efficient way to connect
a six-month cohort period, plans Relavo is a medical device venture students and faculty members at
for future growth, and potential developing the PeritoneX, which academic institutions for research
for impact. Parity’s mission is to prevents infection in peritoneal collaboration. More than 2,000
rehabilitate vacant and abando- dialysis and allows patients with students and faculty members,
ned properties in distressed neig- kidney failure to receive higher as well as six colleges and
hborhoods to create affordable quality care in the comfort of universities nationwide, currently
homeownership opportunities. their homes. use ForagerOne’s platform at
Johns Hopkins.
FY200013
ANNUAL REPORT
<<<< 102019
Annual Report

FASTFORWARD U ACCELERATOR PROGRAM

STUDENT STATS
Johns Hopkins student teams work collaboratively and

108
VENTURES
1,326
STUDENTS ENGAGED
advance their ventures through FFU‘s Accelerator
program. The two tracks in the program provide
SUPPORTED
students support at different stages in the development
IN PROGRAMMING
of their work. Spark is designed for early-stage teams
to validate their ideas, while Fuel is best suited for late-
$232K stage ventures to prepare them for market.
GRANTS AWARDED
The accelerator program culminates during FFU’s
Demo Day, when teams pitch their ventures for the
FFU ACCELERATOR opportunity to win nondilutive funding. This year’s
Spring Demo Day was held virtually and included eight

90+
APPLICATIONS
19
TEAMS
Fuel teams and 11 Spark teams competing against one
another for a prize pool of $30,000.

PARTICIPATING

8
SPARK AND
$112K
FUNDING
FUEL WINNERS AWARDED

SIL IMPACT 2011–2020 THE SOCIAL INNOVATION LAB

The Social Innovation Lab (SIL) provides social

93
VENTURES
258
PAID EMPLOYEES
entrepreneurs the funding, mentorship, office space,
and workshops they need to develop into thriving,
SUPPORTED AT VENTURES
sustainable ventures that have a measurable impact.
Focused on catalyzing the Baltimore-area innovation
ecosystem, SIL invites community members to
$67M participate in addition to Johns Hopkins students,
faculty members, and staff members.
FUNDING SECURED

SIL’s cohort-based learning model offers a six-month

SIL 2019–2020 COHORT program during which innovators and entrepreneurs
support one another on their pathway to scale. Each

50%
WOMEN-LED
70%
BIPOC-LED
October, SIL conducts a competitive application
process during which Baltimore-area residents and
JHU students, faculty members, and staff members
VENTUES VENTURES
can apply for support for their social ventures.

SIL is looking for talented teams and individuals with

innovative ideas that have the potential to sustainably

70%
deliver social impact. The program culminates with SIL’s

COMMUNITY-MEMBER-
$421K
FUNDING SECURED
Impact Forum. This year, the event was held virtually.

For a detailed account of the year, read the 2019-2020

LED VENTURES SIL Impact Report.
 11 FY20 ANNUAL REPORT

TRAINING AND EDUCATION

JHTV is committed to the cultivation of a deep, diverse pool of commercialization talent in and around
Johns Hopkins. This includes training of students in the 'business of science,' educating and equipping
investigators to be translationally-savvy, and ensuring diversity and inclusion in the campus innovation
community.

COMMERCIALIZATION ACADEMY WOMEN IN INNOVATION I-CORPS PROGRAM

The JHTV Commercialization This was the year of female Since 2015, the National Science
Academy provides exposure to inventorship at Johns Hopkins! Foundation I-Corps program has
careers in technology transfer and Our community is rich with women been an integral part of creating a
entrepreneurship for full-time JHU pioneers in myriad fields who are commercialization culture. I-Corps
students. In this two-year, part-time striving to impact the world, yet fills the fundamental educational
fellowship program, students are women are underrepresented in disconnect between invention and
exposed to the day-to-day methods commercialization here and across market that is not found inside a lab or
and approaches taken by JHTV the academic community. Funded by classroom but only through customer
professional staff members, corporate a Small Business Administration grant, interviews. As an I-Corps Node, JHU’s
licensees and entrepreneurs. This JHTV launched the AccelHERator, goal has been to advance knowledge
experience adds to participants’ a four-part event series to facilitate and understanding of the commer-
contributions in their research labs learning and community building in cial potential of life and basic science
and in the innovation community, the hope that women’s contributions research, while providing access to
and ultimately to their future as to discovery will manifest in JHU’s life science expertise in areas
professionals, whether in the field proportionate translational activity. including translation, partnering,
of technology transfer or industry or We also crowdsourced a celebration and entrepreneurship for the greater
nonprofit research. In fiscal year of the Johns Hopkins women whose innovation ecosystem. To date, more
2020, the program expanded to academic ingenuity will change the than 200 teams have engaged directly
include more than 32 student fellows world. Read about the initiative and with our I-Corps programming, which
from across five JHU schools, ranging meet our rock stars. challenges participants to test their
from undergraduate to postdoc and hypothesis on their technology’s
boosted by the program’s first full- relevance and viability through
time manager and a philanthropic customer discovery, which will lead
gift from alum Emmett Cunningham. to viable value propositions. Three
For an exclusive glimpse into the life short course programs are provided
of a fellow, read Maya Lapinski‘s per year, and they are open to
reflection on the valuable experiences teams outside of JHU and will be
she had while working at JHTV. disseminated more broadly
to the tech community.
 FY20 ANNUAL REPORT 11 12

ACKNOWLEDGEMENTS
JHTV is grateful for the support of many generous stakeholders, especially its donors, corporate
sponsors, mentors, and strategic advisers. Each has a key role in our continued success. Donor and sponsor
contributions enable us to fund the innovators, programs, and grants that move ideas from lab to market.
Strategic guidance from our Innovation, Development, and Entrepreneurship Advisory (IDEA) Board
generates growth to entrepreneurship across The Johns Hopkins University and our region. Our alumni,
mentors, and volunteers provide direct guidance to Johns Hopkins innovators and help allocate
translational grant funding that catalyzes technology development. This dedicated team is critical to our
vision of promoting innovation on a local and global scale.

For more information, contact Maddy Stokes, Director, Innovation Initiatives

and Corporate Relations at mstokes@[Link]

DONORS IDEA BOARD

Abell Foundation Brian Bizoza
Stephen and Renee Bisciotti Foundation Inc. Louis Brown Jr.
Brown Advisory Chuck Clarvit
Louis Brown Jr. Nick Culbertson
Chuck and Nancy Clarvit George Davis
Emmett T. Cunningham Jr. Bob Embry
Johns Hopkins Federal Credit Union Scott Ferber
David L. Koch Susan Ganz
Ethan and Karen Leder Justin Hanes
Susy Ganz and the Lion Brothers Company Michael Hankin
Microsoft Corp. Nancy Howard
Migliara Family Foundation Isaac Kinde
James and Mary Miller Ethan Leder
Ralph and Becky O’Connor Joe Migliara
Morris W. Offit Mary Miller
Jeff and Laura Raider Heather Murren
Karthik Seshan Morris Offit
Yury Yakubchyk and Sprout Therapy Chandra Ramanathan
Louis B. Thalheimer
Noga and Antonio Villalon

MENTORS SPONSORS
More than 30 individuals provided mentorship to our AbbVie Newmark Knight Frank
student, social, and professional ventures. We thank, AstraZeneca Pfizer
in particular, our Mentors-in-Residence and those who Bayer PNC Bank
provided extensive engagement to guide significant Biogen Saul Ewing Arnstein & Lehr
projects forward. Bloomberg Philanthropies SC&H Group
CSC Leasing Solidworks
Ethan Agarwal Ian McLane Danaher Diagnostics Thermo Fisher
Sam Ball Brau Bill McNamara Deloitte Venable
Sidd Chhabra Joseph M. Migliara DLA Piper Whiteford Taylor Preston
Arthur (Skip) Colvin Guy Miller Emergent
Graham Dodge Todd Murphy Genentech
AJ Donelson Michael Richman Microsoft Corp.
Yair Flicker Daniel J. Roche
Chris Ganan Ria Shah
Richard (Ric) Hughen Stewart Sweeney
Blythe Karow Sean R. Tunis
Jordan Matelsky Barbara White
 13 FY20 ANNUAL REPORT

WHAT‘S NEXT? SUCCESS STORY

Fiscal year 2020 will go down in JHTV history as a year that challenged our team and our business in
both pragmatic and profound ways. We learned how to use Zoom virtual backgrounds and breakout
rooms, how to hold virtual events, and a lot about coronaviruses. We considered how to act
responsibly in the face of an economic crisis and how to respond to a national reckoning with
systemic racism.

Despite the obstacles and new opportunities presented along our journey, we are committed to
our FY19–FY23 road map that will enable us to deepen our contributions to the academic pursuit of
impact on the world. Some themes you’ll see us tackle in fiscal year 2021 include faculty education,
the commercialization of new therapeutic modalities, the talent pipeline (and its diverse composition)
and the strength of our ecosystem.
JOHNS HOPKINS
TECHNOLOGY VENTURES
FY20 ANNUAL REPORT

1812 Ashland Avenue

Suite 110
Baltimore, MD 21205
[Link]